Dr. Hashmi on Imaging Modalities in Prostate Cancer

Video

Mehmood Hashmi, MD, assistant professor of medicine, University of Kansas Medical Center, discusses imaging modalities in prostate cancer.

Mehmood Hashmi, MD, assistant professor of medicine, University of Kansas Medical Center, discusses imaging modalities in prostate cancer.

Traditionally, physicians use CT scans or bone scans in patients with prostate cancer. Although they help physicians identify a patient’s disease, their sensitivity is not that high. It hovers around 60% to 65%, says Mehmood. Therefore, more advanced modalities are needed to identify the patients who need more aggressive treatment upfront and those who can potentially avoid unnecessary treatment.

Although carbon-11 (C-11) PET scan is a modality that is included in the NCCN guidelines and has approximately 80% sensitivity, it is not readily available at all centers. Prostate-specific membrane antigen (PSMA)-PET scans is another approach that is becoming more common in practice. PSMA scans show higher sensitivity and higher positive predictive values, explains Mehmood.

All of these modalities will help physicians identify the patients who can be treated aggressively in the beginning, as well as those who can avoid unnecessary aggressive surgeries and radiotherapy toxicities, states Mehmood.

Related Videos
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Zeynep Eroglu, MD
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Ramez N. Eskander, MD